This section is intended for patients prescribed ADCETRIS in Great Britain. If you are a member of the public in Great Britain click here. If you are a GB healthcare professional click here.
C-ANPROM/UK/ADCE/0037 - December 2021
ADCETRIS (brentuximab vedotin) is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects whilst taking ADCETRIS, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed on this website or in the patient information leaflet.
You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
By reporting side effects you can help provide more information on the safety of this medicine.
The link you have selected is not under the review or control of Takeda UK Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it.
Please confirm you wish to follow this link.
The link you have selected is not under the review or control of Takeda Products Ireland Limited and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it.
Please confirm you wish to follow this link.
You are now leaving the ADCETRIS.co.uk website. The link you have selected will now take you to the Takeda UK website.
Please confirm you wish to follow this link.
You are now leaving the ADCETRIS.co.uk website. The link you have selected will now take you to the Takeda global website. Takeda UK does not manage or maintain the content of the global website.
Please confirm you wish to follow this link.
You are now leaving the ADCETRIS.co.uk website. The link you have selected will now take you to the Takeda global website. Takeda UK does not manage or maintain the content of the global website.
Please confirm you wish to follow this link.
C-APROM/UK/ADCE/0094 - March 2021